2cureX AB (ST:2CUREX) — Market Cap & Net Worth
Market Cap & Net Worth: 2cureX AB (2CUREX)
2cureX AB (ST:2CUREX) has a market capitalization of $1.13 Million (Skr10.54 Million) as of September 17, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30620 globally and #708 in its home market, demonstrating a -30.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 2cureX AB's stock price Skr0.42 by its total outstanding shares 25102916 (25.10 Million). Also see 2cureX AB total assets for a full breakdown of the balance sheet.
2cureX AB Market Cap History: 2017 to 2026
2cureX AB's market capitalization history from 2017 to 2026. Data shows change from $15.70 Million to $1.13 Million (-28.12% CAGR). Also see 2cureX AB cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
2cureX AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$15.25 Billion | 0.01% | #236 of 281 |
Weight: 2cureX AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
2cureX AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 2cureX AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for 2cureX AB for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
35.03x
2cureX AB's market cap is 35.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $15.70 Million | $47.00K | -$3.14 Million | 334.02x | N/A |
| 2018 | $36.30 Million | $7.67 Million | -$7.26 Million | 4.73x | N/A |
| 2019 | $36.88 Million | $11.98 Million | -$7.93 Million | 3.08x | N/A |
| 2020 | $44.71 Million | $15.39 Million | -$7.32 Million | 2.90x | N/A |
| 2021 | $45.38 Million | $7.39 Million | -$18.94 Million | 6.14x | N/A |
| 2022 | $22.02 Million | $90.00K | -$29.77 Million | 244.63x | N/A |
| 2023 | $5.43 Million | $155.00K | -$32.52 Million | 35.03x | N/A |
Competitor Companies of 2CUREX by Market Capitalization
Companies near 2cureX AB in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of 2cureX AB to assess the quality of the company's equity after excluding intangible assets.
Key companies related to 2cureX AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
2cureX AB Historical Marketcap From 2017 to 2026
Between 2017 and today, 2cureX AB's market cap moved from $15.70 Million to $ 1.13 Million, with a yearly change of -28.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.13 Million | -18.29% |
| 2025 | Skr1.39 Million | +21.80% |
| 2024 | Skr1.14 Million | -79.00% |
| 2023 | Skr5.43 Million | -75.34% |
| 2022 | Skr22.02 Million | -51.49% |
| 2021 | Skr45.38 Million | +1.51% |
| 2020 | Skr44.71 Million | +21.25% |
| 2019 | Skr36.88 Million | +1.59% |
| 2018 | Skr36.30 Million | +131.22% |
| 2017 | Skr15.70 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of 2cureX AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.13 Million USD |
| MoneyControl | $1.13 Million USD |
| MarketWatch | $1.13 Million USD |
| marketcap.company | $1.13 Million USD |
| Reuters | $1.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 2cureX AB
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.